IRS1-Independent Defects Define Major Nodes of Insulin Resistance  by Hoehn, Kyle L. et al.
Cell Metabolism
ArticleIRS1-Independent Defects Define
Major Nodes of Insulin Resistance
Kyle L. Hoehn,1 Cordula Hohnen-Behrens,1 Anna Cederberg,1 Lindsay E. Wu,1 Nigel Turner,1 Tomoyuki Yuasa,2
Yousuke Ebina,2 and David E. James1,*
1Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
2Division of Molecular Genetics, Institute for Enzyme Research, University of Tokushima, 2-24 Shinkura-cho, Tokushima 770-8501, Japan
*Correspondence: d.james@garvan.org.au
DOI 10.1016/j.cmet.2008.04.005Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc. 421SUMMARY
Insulin resistance is a common disorder caused by
a wide variety of physiological insults, some of which
include poor diet, inflammation, anti-inflammatory
steroids, hyperinsulinemia, and dyslipidemia. The
common link between these diverse insults and insu-
lin resistance iswidely considered to involve impaired
insulin signaling, particularly at the level of the insulin
receptor substrate (IRS). To test this model, we uti-
lized a heterologous system involving the platelet-
derived growth factor (PDGF) pathway that recapitu-
latesmany aspects of insulin action independently of
IRS. We comprehensively analyzed six models of in-
sulin resistance in three experimental systems and
consistently observed defects in both insulin and
PDGF action despite a range of insult-specific de-
fects within the IRS-Akt nexus. These findings indi-
cate that while insulin resistance is associated with
multiple deficiencies, the most deleterious defects
and the origin of insulin resistance occur indepen-
dently of IRS.
INTRODUCTION
Insulin plays an essential role in metabolic homeostasis in mam-
mals by accelerating the disposal of postprandial glucose into
muscle and adipose tissue. This step is mediated via the insu-
lin-regulated translocation of the glucose transporter GLUT4
from intracellular vesicles to the plasma membrane. This pro-
cess is imperative, as mice lacking GLUT4 in muscle or fat are
insulin resistant (Minokoshi et al., 2003), a condition defined as
an impairment in insulin-stimulated glucose entry into these tis-
sues. Insulin resistance and the associated glucose intolerance
are important metabolic markers that predispose individuals to
more severe disorders including type 2 diabetes. The origin of
and the precise mechanism (or mechanisms) mediating insulin
resistance are unknown. However, since glucose entry into the
cell represents the earliest rate-limiting defect in insulin-resistant
skeletal muscle (Petersen and Shulman, 2006), this suggests
that the etiology of insulin resistance derives from a lesion in
the pathway between the insulin receptor (IR) and GLUT4.
The precise path from the IR to GLUT4 is still unknown; how-
ever, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway isessential for insulin-regulated glucose metabolism. The insulin-
dependent phosphorylation of insulin receptor substrate (IRS)
proteins is the initial step in the activation of PI3K that leads
to the generation of phosphatidylinositol 3,4,5-trisphosphate
(PIP3), which serves as a docking site for pleckstrin homology
(PH) domain-containing proteins such as PDK1 and Akt. Akt is
the pleiotropic kinase essential for most of the metabolic actions
of insulin, and its activity is regulated by phosphorylation at
Thr308 by PDK1 and Ser473 by the mTOR/Rictor complex. In
many cases, Akt substrates that directly control metabolic steps
havebeen identified; someof these includeglycogensynthaseki-
nase 3 (GSK3) (Cross et al., 1995), the transcription factor FOXO
(Biggs et al., 1999; Paradis and Ruvkun, 1998), the Rheb GAP tu-
berous sclerosis protein 2 (TSC2) (Potter et al., 2002), the phos-
phodiesterase PDE3B (Kitamura et al., 1999), and the Rab GAP
TBC1D4/AS160 (Kane et al., 2002). The last of these, TBC1D4,
is the only Akt substrate that has been shown to play an important
role in insulin-stimulated GLUT4 translocation (Kane et al., 2002).
It shouldbenoted thatAkt-independentpathwayshavealsobeen
implicated in insulin action (Baumann et al., 2000; Farese et al.,
2007); however, their role remains controversial (Huang and
Czech, 2007). One possibility is that these pathways play a per-
missive rather than a regulatory role in insulin action. Regardless,
their relevance to the development of insulin resistance inmuscle
and fat cells remains doubtful, particularly since some of these
pathways appear to be cell type specific (e.g., c-Cbl).
While defects at any one of these loci between the IR and
GLUT4 may contribute to insulin resistance, it is widely believed
that defects at IRS1 represent a central feature of this disorder
(Aguirre et al., 2000; Dresner et al., 1999; Gao et al., 2002,
2003; Gual et al., 2005; Hotamisligil et al., 1996; Morino et al.,
2005; Ozcan et al., 2004; Rice et al., 1993; Turnbow et al.,
1994; Ueki et al., 2004; White, 2002; Yu et al., 2002; Zick,
2005; Zierath et al., 1997). To date, considerable evidence has
focused on IRS proteins as a major target of insulin resistance
under a broad range of conditions. Several mechanisms have
been reported to modify the activity of IRS, including protein/
protein interactions, Ser/Thr hyperphosphorylation, tyrosine
dephosphorylation, targeted degradation, and other posttrans-
lational modifications such as O-linked glycosylation and acety-
lation (reviewed in Gual et al., 2005; Taniguchi et al., 2006).
There are several caveats to the model describing a major role
for IRS proteins in insulin resistance. First, many studies of IRS
function in insulin resistance focusonelements in thesignal trans-
duction cascade as the major readout of insulin resistance rather
than terminal actions of insulin such as GLUT4 insertion into the
Cell Metabolism
IRS-Independent Mechanisms of Insulin Resistanceplasma membrane. Second, there is evidence that insulin resis-
tance is not always associated with defects in Akt activity
(Kim et al., 1999; Nadler et al., 2001). Third, as originally shown
byKonoandcolleagues (KonoandBarham,1971) for the IR, there
is often considerable ‘‘spareness’’ in various elements of the insu-
lin signaling cascade, and the same applies to IRS1 (Rice et al.,
1992). This means that incomplete inhibition of IRS may not
have a major impact on metabolism. Consistent with this, mice
heterozygous for IRS1do not showdefects in insulin action under
normal conditions (Shirakami et al., 2002), andpartial knockdown
of IRS1 in skeletal muscle has no effect on insulin action (Cleasby
et al., 2007). Thus, it remains unclearwhether reduced insulin sig-
naling through IRS is a primary cause of insulin resistance or sim-
ply a secondary consequence of an alternate primary disorder.
RESULTS
Lack of Linearity between Akt and GLUT4
Akt has been shown to play an essential role in many actions of
insulin, including GLUT4 translocation (Kohn et al., 1996). How-
ever, as shown in Figure 1, the dynamic range of Akt activity with
respect to substrate phosphorylation andGLUT4 translocation is
considerably lower than its maximal capacity. This is consistent
with previous reports showing a similar nonlinearity between
insulin-stimulated Akt activation and glucose uptake (Whitehead
et al., 2001). Strikingly, the dose-response relationship of Akt
substrate phosphorylation was discordant with that of insulin-
stimulated Akt phosphorylation, and a further discordance was
observed between distinct Akt substrates (Figure 1C). In adipo-
cytes incubated with 0.1–1 nM insulin, a concentration within the
high physiological range, GLUT4 translocation and TBC1D4
phosphorylation increased to 50% of their maximum values
while Akt and GSK3 phosphorylation reached only 20% of their
maximum output. The discordance between insulin-activated
TBC1D4 phosphorylation is not likely due to an additive contribu-
tion of other insulin-stimulated upstream kinases on TBC1D4,
because its phosphorylation was inhibited using a specific Akt
inhibitor (Figure 1D). Furthermore, insulin had a maximal effect
on GLUT4 translocation in L6myotubes at concentrations where
only 5% of the total Akt pool was phosphorylated (Figure 1E).
Figure 1. Insulin-Stimulated GLUT4
Translocation Is Not Proportional to Akt
Phosphorylation
(A) 3T3-L1 adipocytes were treated with a dose re-
sponse of insulin. At each dose, the phosphoryla-
tion status of Akt at Ser473, GSK3a/b at Ser9/21,
and TBC1D4 at Thr642 were detected by western
blot.
(B) Under the same insulin treatment conditions,
GLUT4 translocation to the plasma membrane
(PM) was detected using the GLUT4 translocation
assay described in Experimental Procedures.
Results are presented as means ± SEM of 3–4
experiments.
(C) To directly compare the insulin-stimulated re-
sponse of each parameter in (A) and (B), the west-
ern blots and translocation data were quantified
and normalized to 0 and 100 nM insulin, represent-
ing minimal and maximal stimulation. An evalua-
tion of submaximal stimulation reveals a distinct
nonlinearity between Akt phosphorylation and
GLUT4 translocation to the plasma membrane.
However, phosphorylation of TBC1D4 at submax-
imal insulin levels is more consistent with GLUT4
translocation than Akt, indicating an increased ac-
tivity toward this substrate over others like GSK3.
Results are presented as means ± SEM of 3–4 ex-
periments. *p < 0.05 relative to Akt phosphoryla-
tion at the given dose of insulin by Student’s t test.
(D) The PI3K inhibitor wortmannin (WT, 100 nM for
10 min prior to insulin) and an Akt inhibitor (at con-
centrations of 0.1, 1, and 10 mM) inhibit Akt phos-
phorylation and subsequent phosphorylation of
TBC1D4 in 3T3-L1 adipocytes treatedwith 100 nM
insulin for 12 min, indicating that Akt is the sole
insulin-regulated kinase acting on this site.
Representative western blots of three separate
experiments are shown.
(E) Insulin (20 min) was added to L6 myotubes at
the concentrations indicated, and the Akt phos-
phorylation and GLUT4 translocation responses
were analyzed as a percent of maximal stimula-
tion. Results are presented as means ± SEM,
n = 3. *p < 0.05 by Student’s t test.422 Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc.
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signaling and insulin action not previously emphasized. First,
there is considerable spareness in the activity of Akt in vivo
with respect to insulin action as defined by GLUT4 translocation.
Second, there is discordance in the efficiency of Akt substrate
phosphorylation such that certain substrates such as TBC1D4
are more efficiently phosphorylated than others such as GSK3.
One ramification of these data is that a modest defect in up-
stream elements of the insulin signaling cascade per se, as is
often described in insulin resistance, may not translate into
downstream defects due to spareness in the pathway. To test
this hypothesis, we conducted an extensive analysis of the insu-
lin action pathway in a variety of models of insulin resistance.
PDGF Mimics Insulin Action Independently of IRS
To dissect the specific role of IRS in insulin resistance, we estab-
lished an experimental system utilizing the platelet-derived
growth factor (PDGF) pathway to bypass the requirement for
IRS while preserving other elements of the insulin action cas-
cade. Muscle and fat cells do not possess sufficient levels of
the PDGF receptor to trigger a PDGF response in these cells
(Whiteman et al., 2003; unpublished data). Therefore, the human
PDGF b receptor (PDGFR) was ectopically expressed in mouse
3T3-L1 preadipocytes and rat L6 myoblasts using recombinant
retrovirus (Figure 2A;Whiteman et al., 2003). Upon differentiation
into adipocytes or myotubes, we evaluated insulin and PDGF ac-
tion to define the optimal doses and incubation times with ligand
to achieve the most consistent amplification of signal trans-
duction and GLUT4 translocation (data not shown). In both cell
culture models, a maximum dose of insulin (100 nM) and PDGF
(20 ng/ml) was utilized, as this produced a consistent and similar
response facilitating a direct comparison between both agonists
(see Figure 2B). Both hormones activated PI3K without detect-
able crosstalk at the level of IRS1 as indicated by the absence
of PDGF-stimulated IRS1 tyrosine phosphorylation at the PI3K
binding site (Tyr612), compared to the robust phosphorylation
observed with insulin. Conversely, whereas PDGF stimulated
tyrosine phosphorylation of the PDGF receptor in bothmyotubes
and adipocytes, this was not observed in response to insulin
stimulation (Figure 2B). Importantly, both insulin and PDGF stim-
ulated Akt and TBC1D4 phosphorylation and GLUT4 transloca-
tion with similar amplitude (Figures 2B and 2C) and kinetics
(data not shown) in both cell types. Consistent with previous
studies (Whiteman et al., 2003), these data show that IRS pro-
teins are not necessary for PDGF-induced GLUT4 translocation
but are rather a specific feature necessary for other aspects of
insulin action. Hence, this offers an ideal experimental system
with which to assess the role of IRS proteins in insulin resistance.
Bypassing IRS Does Not Override Insulin Resistance
To study the role of IRS in insulin resistance, we next generated
a range of metabolic disorders in L6 myotubes or 3T3-L1 adipo-
cytes overexpressing PDGFR using insults that recapitulate
common causes of insulin resistance in mammals, including hy-
perinsulinemia (chronic insulin, CI), inflammation (tumor necrosis
factor a, TNF), Cushing’s syndrome/anti-inflammatory steroids
(dexamethasone, DEX), and hyperlipidemia/dyslipidemia (palmi-
tate, PALM). Oxidative stress, which has also been linked to
insulin resistance (Houstis et al., 2006; Kaneto et al., 2005), wasgenerated by incubating cells with glucose oxidase (GO). To
avoid toxic or nonspecific effects, the treatment dose and/or du-
ration for all insults was optimized to define minimal conditions
required to elicit maximal insulin resistance (data not shown).
GO, CI, TNF, DEX, and PALM inhibited insulin-stimulated GLUT4
translocation by 45%–60% in both 3T3-L1 and L6 cells, indicat-
ing marked insulin resistance with each model (Figure 3). How-
ever, PDGF was unable to overcome these defects, indicating
that IRS1 per se is not a major contributor to insulin resistance
(Figure 3). Notably, however, we did observe a consistent resto-
ration of GLUT4 translocation with PDGF in myotubes, and to
Figure 2. PDGF Mimics Insulin Action While Circumventing the
Insulin Receptor and IRS
(A) The human PDGF receptor (PDGFR) was ectopically overexpressed in
mouse 3T3-L1 adipocytes and rat L6 myotubes. Representative western blots
of PDGFR expression are shown. Pa, preadipocytes; Ad, adipocytes; Mb,
myoblasts; Mt, myotubes.
(B) PDGFR-expressing adipocytes (left panel) andmyotubes (right panel) were
serum starved for 90min prior to acute stimulation with either 100 nM insulin or
20 ng/ml PDGF for 20 min. Representative western blots of cell and tissue
extracts show similar amplification of insulin- and PDGF-stimulated signaling
intermediates.
(C) Insulin- and PDGF-stimulated GLUT4 translocation to the plasma mem-
brane as a percentage of total HA-GLUT4 in adipocytes (left panel) and myo-
tubes (right panel). In both cell types, insulin was slightly more potent than
PDGF (89% ± 2% and 90% ± 3% of maximal insulin for adipocytes and myo-
tubes, respectively). Results are presented as means ± SEM of 5 experiments
of >3 measurements each.Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc. 423
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phasizes the utility of this system, clearly indicating that in the
case of the CI model, the major defect must occur at compo-
nents unique to the insulin pathway involving either the IR or
IRS1.
Upstream Signal Transduction in Insulin Resistance
We next examined IRS1 expression and phosphorylation since
defects in both of these parameters have been reported in
many insulin-resistance models. A significant reduction in IRS1
protein levels was observed in adipocytes treated with CI,
TNF, and DEX, consistent with previous studies (Figure 4A).
However, this did not consistently correlate with changes in insu-
lin-stimulated IRS1 tyrosine phosphorylation as exemplified in
cells treated with DEX. Moreover, we observed uncoupling be-
tween IRS1 tyrosine phosphorylation and downstream signaling
in adipocytes treated with CI. In this instance, we observed per-
sistent tyrosine phosphorylation of IRS1 following chronic insulin
treatment despite an extensive insulin washout period. The insu-
lin washout was clearly effective because Akt phosphorylation
had returned to basal levels (see CI, Figure 4A). Hence, this sug-
gests that additional aspects of IRS1 function, such as subcellu-
lar localization (Clark et al., 1998; Inoue et al., 1998), may play an
important role in its coupling to downstream signaling elements.
Finally, GO treatment had no effect on IRS1 tyrosine phosphor-
ylation or abundance despite significant insulin resistance
(Figure 3A), indicating that this insult likely functions downstream
of IRS as suggested recently (JeBailey et al., 2007).
Figure 3. Multiple Insults Antagonize Insulin and PDGF Action
(A) GLUT4 translocation to the plasmamembrane wasmeasured after glucose
oxidase (GO, 50 mU/ml for 2 hr), chronic insulin (CI, 10 nM for 24 hr), TNFa
(TNF, 2 ng/ml for 4 days), or dexamethasone (DEX, 20 nM for 8 days) treatment
in 3T3-L1 adipocytes stimulated with insulin or PDGF.
(B) GLUT4 translocation to the plasma membrane was analyzed in L6
myotubes treated with the above conditions or palmitate (PALM, 150 mM for
18 hr). All data were normalized to maximum stimulation with 100 nM insulin
for each cell type.
Results are displayed as means ± SEM of 3–5 experiments for each data set.
*p < 0.05 versus respective insulin- or PDGF-stimulated control (Ø) by
Student’s t test.424 Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc.We next focused on Akt to determine whether the changes in
IRS function described above were transmitted distally through-
out the insulin signaling cascade. Phosphorylation of Akt at both
Thr308 and Ser473wasmeasured as an index of its activation by
upstream regulators. To determine the in vivo activity state of
Akt, the phosphorylation of TBC1D4, a key target of Akt involved
in GLUT4 translocation (Kane et al., 2002; Larance et al., 2005),
was measured. We and others have shown that Thr642 is one of
the key Akt substrate sites in TBC1D4 that plays an essential role
in its function (Kane et al., 2002; Ramm et al., 2006; Sano et al.,
2003). Therefore, a phosphorylation-specific antibody targeting
this site was produced and used to probe cell lysates.
Consistent with changes in IRS function, we observed a signif-
icant reduction in Akt phosphorylation in cells treated with CI,
TNF, and DEX, but not in cells treated with either GO or PALM
(Figure 4B). These data are consistent with previous reports
showing upstream signaling defects upon treatment with CI,
TNF, and DEX (Aguirre et al., 2000; Ball et al., 2006; Hotamisligil,
1999; Houstis et al., 2006; Ishizuka et al., 2007; Paz et al., 1997;
Saad et al., 1993; Sun et al., 1999; Turnbow et al., 1994). Interest-
ingly, PDGF treatment overcame the defect in Akt activation in
cells treated with CI and TNF, but not in cells treated with DEX.
To determine whether these changes in Akt phosphorylation
resulted in defective Akt signaling, we next examined TBC1D4
phosphorylation (Figure 4C). Surprisingly, we observed a com-
plete discordance between these parameters. For example,
there was no effect of GO on either insulin- or PDGF-stimulated
Akt phosphorylation (Figure 4B), whereas the specific activity
of TBC1D4 phosphorylation was significantly diminished (Fig-
ure 4C). Conversely, with CI, despite reduced insulin-stimulated
Akt phosphorylation, TBC1D4 phosphorylation was unimpaired
(Figure 4C). This highlights a degree of spareness at the level
of Akt as described in Figure 1. TNF-treated cells exhibited a dis-
tinct phenotype at the level of TBC1D4 compared with either
GO- or CI-treated cells. Here we observed a dramatic reduction
in TBC1D4 protein levels. Despite this, the specific activity of
TBC1D4 phosphorylation at Thr642 was unchanged in response
to either insulin or PDGF. Again this emphasizes the spareness in
these signaling intermediates because TBC1D4 is believed to be
a negative regulator of GLUT4 translocation under basal condi-
tions and phosphorylation overcomes this negative regulation
(Kane et al., 2002; Larance et al., 2005; Ramm et al., 2006).
Hence, it is notable that cells were able to tolerate this substan-
tial reduction in TBC1D4 levels with only a mild increase in basal
cell surface levels of GLUT4 (Figure 3A). Intriguingly, DEX yielded
changes at the level of TBC1D4 that were diametrically opposed
to TNF. TBC1D4 total protein levels and Thr642 phosphorylation
in response to insulin and PDGF were significantly enhanced in
these cells. Considering that both TNF and DEX caused signifi-
cant insulin resistance at the level of GLUT4 translocation, these
data suggest that intermediates such as TBC1D4 may operate
as regulated switches with an intrinsic threshold such that mod-
est defects upstream of this molecule may not directly translate
downstream.
Effects of Palmitate on Insulin Action
The most striking discrepancy between Akt activation and
GLUT4 translocation was observed in L6 myotubes incubated
with palmitate. In the presence of 150 mM palmitate, insulin- and
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IRS-Independent Mechanisms of Insulin ResistanceFigure 4. Signal Transduction in 3T3-L1 Adipocytes and L6 Myotubes Treated with Multiple Models of Insulin Resistance
Cells were left in unstimulated basal conditions or stimulated with insulin or PDGF.
(A) Representative western blots and quantitative bar graphs are shown for the detection of PDGFR and IRS1 tyrosine phosphorylation and total IRS1 protein
levels. The phospho-Tyr612 IRS1 (pY-IRS1) antibody detects phosphorylation of the PI3K binding site in both molecules.
(B) Representative western blots and quantification of Akt Ser473 and Thr308 phosphorylation and total Akt levels.
(C) Cell lysates were probed for TBC1D4 phosphorylation at Thr642 and total TBC1D4 expression. The bottom panel represents a quantification of phosphor-
ylated to total TBC1D4 (p/t-TBC1D4).
Western blots are representative and statistical values are displayed as means ± SEM of 3–5 experiments. *p < 0.05 versus respective control (Ø) by Student’s
t test.Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc. 425
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(Figure 3B) without any observed signaling defects at IRS1,
Akt, or TBC1D4 (Figure 4). This was surprising, as other investi-
gators have described defects in insulin signaling following incu-
bation of either adipocytes or myotubes with palmitate (Powell
et al., 2004; Sinha et al., 2004). However, many of these studies
utilized much higher doses of palmitate to achieve these effects
than those used in the present study. In our preliminary inves-
tigations, we observed that high (>300 mM) palmitate doses
were toxic to cells, resulting in morphological changes and
even detachment from the substratum. Hence, we further char-
acterized the dose-response relationship between palmitate and
insulin action. We observed a significant reduction in insulin-
stimulated GLUT4 translocation with palmitate doses as low as
50 mM, reaching a maximum diminution at 150 mM (Figure 5A).
Figure 5. Palmitate Antagonizes Insulin Action at
GLUT4 without Disrupting Signal Transduction
through TBC1D4 in L6 myotubes
(A) Basal (white bars) and insulin-stimulated (black bars)
GLUT4 translocation were measured in L6 myotubes incu-
bated with a dose response of palmitate for 18 hr. Results
are presented as means ± SEM of 3 independent experiments
of >3 measurements each. *p < 0.05 between palmitate and
carrier control by Student’s t test.
(B) Representative western blots of phosphorylated and total
IRS1, Akt, and TBC1D4 in palmitate-treated myotubes.
(C) No significant difference was observed in the phosphoryla-
tion of IRS1, Akt, or TBC1D4 between control myotubes and
those treated with up to 300 mM palmitate. However, higher
concentrations severely antagonized insulin action at these
molecules as shown. Results are presented as means ±
SEM. *p < 0.05 between palmitate and control by Student’s
t test.
No defects in either IRS1 expression or insulin-
stimulated IRS1 tyrosine phosphorylation, Akt
phosphorylation, or TBC1D4 phosphorylation
were observed using palmitate concentrations be-
tween 0 and 150 mM (Figures 5B and 5C), whereas
at concentrations exceeding 300 mM, substantial
defects in each of these signaling parameters
were observed. Again, this model of insulin resis-
tance points to a major node of insulin resistance
distal to IRS/PI3K/Akt and suggests that signaling
defects may arise either as a consequence of insu-
lin resistance per se (i.e., reduced GLUT4 translo-
cation) or independently of insulin resistance, pos-
sibly due to toxic ‘‘off-target’’ effects.
The Role of IRS/Akt in High-Fat-Fed Mice
The above studies indicate that while a range of
signaling defects can be observed in some (GO,
CI, TNF, and DEX), but not all (PALM), models of in-
sulin resistance, it is apparent that there is sufficient
spareness in many of these elements such that
they may represent neither the sole nor the primary
defect. While such cell systems have been invalu-
able in dissecting the molecular basis of insulin
resistance, it is important to determine whether
such findings can be translated to a more physiological setting.
Hence, we next performed a series of studies in transgenic mice
overexpressing PDGFR in muscle. PDGF stimulated signal
transduction and glucose transport to an extent similar to insulin
in isolated soleusmuscle from thesemice (Figures 6A–6C). Thus,
these animals provide a unique system with which to assess
the role of IRS and downstream signaling elements in insulin
resistance in vivo.
We created insulin resistance in this model by dietary modifi-
cation to reflect the physiological impact of poor diet. The diets
consisted of either standard lab chow (8% of calories from fat,
21% of calories from protein, 71% of calories from carbohy-
drates; 2.6 kcal/g) or a high-saturated-fat diet (HFD; 45% of cal-
ories from fat, of which 87% was lard and 13% safflower oil by
weight, 20% of calories from protein, and 35% of calories from426 Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc.
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IRS-Independent Mechanisms of Insulin ResistanceFigure 6. Modulation of Insulin and PDGF Action in High-Fat-Fed PDGFR Transgenic Mice
(A) Intact soleus muscles from transgenic mice were blotted for expression of PDGFR.
(B) Isolated soleus muscles were incubated in vitro and stimulated with 2 mU/ml insulin or 500 ng/ml PDGF for 30 min, and western blots were performed on
whole-cell lysates. Representative blots are shown. Phosphorylation of Akt at Thr308 was undetectable.
(C) PDGF had a more potent effect on 2-[2-6-3H]deoxyglucose (2-DOG) uptake into soleus muscle than insulin in transgenic mice (3.59 ± 0.09 versus 2.78 ±
0.12 mmol 2-DOG/g/hr), consistent with previous studies (Yuasa et al., 2004). Results are presented as means ± SEM, n = 5–7 soleus muscles per group.
(D) Glucose tolerance tests were performed on mice in the 4 hr fasted state to predict insulin resistance. Diet durations of both 17 and 42 days produced
significant reductions in glucose tolerance as indicated by differences in blood glucose levels of mice fed a high-fat diet (HFD) versus the group fed a low-fat
diet (LFD). Individual points are displayed as means ± SEM, n = 7–9 mice per curve. *p < 0.05 between LFD and HFD groups by Student’s t test.
(E) Reduction in insulin-stimulated (hashed bars) and PDGF-stimulated (gray bars) 2-DOG uptake in isolated soleus muscles from mice fed HFD for 17 days
(17% ± 6% and 16% ± 5% of control insulin- and PDGF-stimulated uptake, respectively) or 42 days (29% ± 5% and 15% ± 2% of control insulin- and
PDGF-stimulated uptake, respectively). Results are displayed as means ± SEM, n = 3–7 soleus muscles per data set. *p < 0.05 between LFD and HFD groups
by Student’s t test.
(F) Representative western blots and bar graphs for soleus muscles stimulated with insulin (hashed bars) or PDGF (gray bars) for 30 min. Total protein levels are
shown in white or black bars. Results are displayed as means ± SEM, n = 3–5 soleus muscles per experiment. *p < 0.05 between LFD and HFD groups by
Student’s t test.
(G) Representative western blots and quantification of GLUT4 expression inmice fed LFD or HFD for 17 and 42 days. Results are displayed asmeans ± SEM, n = 4
per group. *p < 0.05 between LFD and HFD groups by Student’s t test.carbohydrates; 4.7 kcal/g). Consistent with other reports (Bon-
nard et al., 2008), we observed glucose intolerance within weeks
of HFD feeding (Figure 6D). To study the mechanism of this ef-
fect, we examined the capacity of insulin and PDGF to increase
glucose uptake and activate signal transduction in this model
(Figures 6E and 6F). HFD feeding for as little as 17 days resulted
in a significant reduction in both insulin- and PDGF-stimulated
2-[2-6-3H]deoxyglucose (2-DOG) uptake, without any detect-
able decrease in GLUT4 levels (Figure 6G) or Akt or TBC1D4
phosphorylation. As was the casewith the cell models describedabove, impaired insulin- and PDGF-stimulated Akt phosphoryla-
tion was apparent only with longer-term dietary treatment (42
days HFD; Figure 6F). It should also be noted that we observed
a significant 30% reduction in total muscle GLUT4 levels in the
42 days HFD animals. Intriguingly, this was accompanied by
an additional decrease in insulin-stimulated, but not PDGF-stim-
ulated, 2-DOG uptake compared to that observed in 17 days
HFD animals. This suggests that IRS-dependent defects might
contribute to a worsening or maintenance of the condition.
These data are consistent with the in vitro PALM data inCell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc. 427
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IRS1 Defect Phospho-Akt Phospho-TBC1D4 GLUT4/2-DOG
Phospho-Tyr Expression Insulin PDGF Insulin PDGF Insulin PDGF Primary Defect
Glucose oxidase     YY YY YY YY IRS-independent
Chronic insulin  YY YY    YY Y IRS-dependent
TNFa YY YY YY    YY YY both
Dexamethasone  YY YY YY   YY YY both
Palmitate       YY YY IRS-independent
17 days HFD       YY YY IRS-independent
Summary of defects in insulin- and PDGF-stimulated signal transduction and GLUT4 translocation (for cell culture models) and 2-DOG uptake (for
animal model). Arrows indicate the severity of the defect for each variable, and minus sign () represents the absence of a defect. The last column
indicates the existence of IRS-dependent and/or -independent defects.myotubes indicating that early defects leading to insulin resis-
tance are not due to impaired IRS/Akt function and that while
defects in Akt phosphorylation are observed with prolonged
HFD, there is sufficient spareness in the system such that these
defects are not necessarily transmitted further down the path-
way since phosphorylation of TBC1D4 remained intact.
DISCUSSION
Defining the mechanism (or mechanisms) of insulin resistance is
challenging. Numerous insults can cause insulin resistance, yet it
has been difficult to establish whether there is a common link be-
tween these disparate triggers. A common dogma in the field is
that IRS proteins represent a major node of insulin resistance for
most of these models (Aguirre et al., 2000; Dresner et al., 1999;
Gao et al., 2002, 2003; Gual et al., 2005; Hotamisligil et al.,
1996; Morino et al., 2005; Ozcan et al., 2004; Rice et al., 1993;
Turnbow et al., 1994; Ueki et al., 2004; White, 2002; Yu et al.,
2002; Zick, 2005; Zierath et al., 1997). In the present study, we
provide evidence that while defects in upstream elements of
the insulin cascade may occur in various insulin-resistance
models, it is unlikely that this is a major cause of impaired
glucose metabolism, the defining feature of insulin resistance.
We have utilized a system enabling us to test the role of IRS
proteins in insulin resistance by comparing the effects of insulin
and PDGF on signaling and metabolism. For example, with
chronic insulin, a significant reduction in insulin-stimulated
GLUT4 translocation was observed whereas PDGF-stimulated
GLUT4 translocation was similar to that observed in control cells.
This indicates that with chronic insulin, the major impairment
likely involves a target specific to the IR, most likely IRS1. This
is consistent with previous literature and acts as an important
control for the present model system. In contrast, in the other
models, which more closely parallel physiologic states of insulin
resistance, we observed a similar impairment in GLUT4 translo-
cation with both ligands. The most extreme discordance
between upstream signaling and GLUT4 translocation was ob-
served in palmitate-treated L6 myotubes and HFD-fed mice.
Here, using either low doses of palmitate or relatively short expo-
sure to HFD, we observed impaired insulin- and PDGF-stimu-
lated GLUT4 translocation and 2-DOG uptake, respectively,
without any detectable defect within the IRS/PI3K/Akt nexus.
This raises the possibility that upstream signaling defects are
a consequence of insulin resistance rather than a cause of the428 Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc.condition. In this scenario, lesions in signal transduction possibly
exacerbate the insulin-resistant state to support a more chronic
and progressive dysfunction resulting in metabolic diseases like
type 2 diabetes. Collectively, these studies suggest that while
defects in IRS/PI3K/Akt may occur in insulin resistance, it is un-
likely that such defects contribute to its early development. Alter-
natively, these signaling defectsmay be completely independent
of the metabolic milieu and may possibly involve cytotoxicity,
a potential consequence of chronic exposure to cytokines,
lipids, and other metabolic insults that in many cases lead to
cellular stress (Bloch-Damti and Bashan, 2005; Evans et al.,
2005; Kaneto et al., 2005).
Amajor problemwithmany studies that have implicated an im-
portant role for upstream signaling elements in insulin resistance
is that they assume that such pathways operate stoichiometri-
cally such that a modest defect in one component will be linearly
transmitted all the way down the pathway. However, our analysis
of insulin action under control and insulin-resistant conditions in-
dicates that these pathways are governed more by a stochastic
operating principle. This can be illustrated by the observation
that only a finite amount of Akt is required to be phosphorylated
in order to orchestrate a maximal biological response (Figure 1).
Moreover, once activated, there is discordance in the ability of
Akt to activate discrete downstream substrates such as
TBC1D4 and GSK3. The nature of this differential transmission
downstream of Akt may involve a role for discrete Akt isoforms,
the unique localization of certain Akt substrates, or the assembly
of unique signaling subcomplexes involving scaffolding proteins,
and this certainly requires further investigation. Careful analysis
of our insulin-resistance models as summarized in Table 1
reveals a somewhat fragmented response pattern in upstream
elements of the pathway, which again is consistent with stochas-
tic regulation involving many negative feedback loops. However,
a unifying feature that emerges from this analysis is that despite
this fragmented pattern upstream, both insulin- and PDGF-stim-
ulated TBC1D4 phosphorylation responded quite normally in the
face of insulin resistance at the level of GLUT4 translocation.
How do insulin-sensitive cells achieve graded outputs in re-
sponse to different concentrations of the relevant agonist given
that the active range of Akt with respect to glucose transport
appears to be extremely finite? One possibility is that signaling
through Akt is a digital rather than an analog response. A similar
mechanism has been described for Ras signaling (Tian et al.,
2007). In addition, we have recently presented a model whereby
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mechanism again consistent with a digital or threshold response
(Larance et al., 2008). Such amechanism likely denotes signaling
subcompartments that are not resolved by the types of analyses
employed in this and many other studies. For example, it has
been suggested that there are critical pools of IRS1 that may
be localized close to the plasma membrane (Clark et al., 1998),
in which case one can envisage that defects in these compart-
ments may disrupt signaling through the pathway in an appar-
ently nonlinear fashion. While we cannot dismiss these possibil-
ities, it seems likely that such adaptations would merely account
for the nonlinearity in the system, thus emphasizing the need to
exercise caution when interpreting analyses involving simple
changes in total levels or the phosphorylation status of such in-
termediates. With this in mind, it is therefore important to con-
sider the output from signaling nodes such as Akt substrate
phosphorylation or GLUT4 translocation, which in both cases
was discordant with the flux through these upstream elements.
How can the present data be interpreted in light of numerous
studies suggesting that IRS1 is the major node of insulin resis-
tance? First, it is noteworthy that many studies have focused
on signaling rather than metabolic endpoints as their index of in-
sulin resistance. Here we utilized GLUT4 translocation or glu-
cose transport as our index of insulin resistance. This is impor-
tant because not only is this process rate limiting for many of
the metabolic actions of insulin, but defects in glucose transport
appear to represent some of the earliest and most significant
defects observed in insulin resistance (Petersen and Shulman,
2006). Moreover, our analysis of GLUT4 translocation was
normalized to the total expression of GLUT4 in the cell, thus
overcoming the contribution of altered GLUT4 expression in
response to insulin-resistance treatments (Hajduch et al., 1992,
1995; Kaestner et al., 1991; Lundgren et al., 2004; Stephens
et al., 1997; Stephens and Pekala, 1992). We also suggest that
this assay is superior to the measurement of cellular glucose
transport or glycogen synthesis, as this is easily influenced by
changes in the expression of alternate transporter isoforms
such as GLUT1, a common feature of in vitro cell culture models
of insulin resistance (Hosaka et al., 1999; Mei et al., 2003;
Sakoda et al., 2000) but not in vivo insulin resistance (Kahn et al.,
1991). Second, many studies have also overlooked the temporal
and/or dose-response characteristics of the metabolic insult
with respect to the onset of insulin resistance. In the present
study, we carefully characterized minimal conditions required
to achieve maximal insulin resistance as defined by inhibition
of GLUT4 translocation to the plasma membrane in cell culture
or glucose uptake in mice. This was essential, as in at least
two models (150 mM palmitate in L6 myotubes and 17 days
HFD in mice) we observed marked insulin resistance without
any significant change in signaling, whereas undermore extreme
conditions signaling defects became apparent. Finally, many
studies implicating IRS proteins in insulin resistance rely on cor-
relative changes between metabolism and IRS Ser/Thr phos-
phorylation in response to various reversal strategies. For in-
stance, inhibition of mTOR with rapamycin or JNK with peptide
and small-molecule drugs has been used in this way, yet these
agents likely impact upon many cellular processes due to their
effect on protein synthesis and gene expression, respectively.
Thus, if insulin resistance is independent of the signaling defectsas suggested here, then any manipulation that corrects insulin
resistance might also potentially override defects in signaling
that derive from the same insult.
A major question arising from these studies is, what are the
molecular targets that contribute to insulin resistance? Based
on the present studies, we conclude that these defects likely oc-
cur downstream of IRS, and in some cases possibly downstream
of Akt. However, in relation to the latter it is important to empha-
size that the regulation of Akt is proving to be quite complex, as
indicated by recent studies showing a role for the Akt-binding
protein APPL1 in insulin-stimulated GLUT4 translocation (Saito
et al., 2007). Hence, thismay invoke some type of nanoregulation
that will be challenging to dissect. This could involve the assem-
bly of signaling modules close to or at the plasma membrane. In
this regard, it is interesting that reduced levels of PIP2 at the cell
surface may disrupt the ability to recruit GLUT4 vesicles to
this site, possibly due to disruptions in the actin cytoskeleton
(McCarthy et al., 2006; Strawbridge and Elmendorf, 2005). This
poses yet another important question: Does insulin resistance
represent a uniform disruption in all of the metabolic actions of
insulin, or is there a temporal progression of defects whereby
an initial defect in glucose transport, for example, could subse-
quently lead to defects in other metabolic parameters such as
glycogen and lipid synthesis? Consistent with such a hypothesis
is the observation that deletion of GLUT4 in adipose tissue re-
sults in insulin resistance in other tissues in the intact animal
(Abel et al., 2001). Hence, this potentially places GLUT4 translo-
cation and glucose transport at the center of this disorder.
In conclusion, these data reveal that upstream elements of the
insulin signaling cascade are not a central feature of the origin of
insulin resistance as commonly thought. While defects in these
upstream signaling elements may be frequently observed in in-
sulin resistance in view of the stochastic nature of the pathway,
such defectsmay ormay not be transmitted further downstream.
Moreover, such defectsmay occur as a consequence of an alter-
nate initial defect, possibly to sustain the insulin-resistant state.
The nature of this initial defect (or defects) remains unknown at
the present time. It is likely that a search for additional Akt sub-
strates and other downstream regulators of this pathway will
be revealing. The identification of such targets will be of enor-
mous utility in the design of targeted therapies for prevention
of insulin resistance. This study provides molecular insight into
the mechanisms and origins of insulin resistance and should fa-
cilitate a renewed focus on the pursuit of new molecular targets
downstream of IRS.
EXPERIMENTAL PROCEDURES
Models of Insulin Resistance
3T3-L1 preadipocytes or L6 myoblasts were infected with replication-in-
competent retroviruses expressing HA-GLUT4 and human PDGF b receptor
and selected with puromycin and Geneticin. Cells were differentiated into
adipocytes or myotubes as described previously (Lee et al., 2006).
Oxidative Stress
Oxidative stress (GO) was induced in 3T3-L1 adipocytes by washing cells
three times in phosphate-buffered saline (PBS) and incubating with serum-
free DMEM supplemented with 0.1% BSA (stepdown medium) containing
50 mU/ml glucose oxidase or carrier (0.16 mM sodium acetate [pH 7.4]) for
2 hr. This generated a final H2O2 concentration of 25.8 ± 0.1 mM,while total glu-
cose levels (measured with an Accu-Chek II glucometer [Roche]) decreased
slightly from 24.7 ± 1.6 mM to 23.3 ± 1.9 mM.Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc. 429
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Chronic low-dose inflammation (TNF) was mimicked in 3T3-L1 adipocytes by
incubation with 2 ng/ml TNFa (Calbiochem) for 4 days. Medium was changed
every 24 hr. On the fourth day, cells were washed three times with PBS and in-
cubated in stepdown medium in the absence of TNFa for 90 min prior to acute
insulin or PDGF stimulation.
Hyperinsulinemia
Hyperinsulinemia (CI) was created by addition of 10 nM insulin to adipocytes at
1200, 1600, and 2000 hr on day 1 and 0800 hr on the following day. At 1200 hr
on the second day, cells were washed 4–5 times with PBS and cultured in
stepdown medium for 90 min before acute insulin or PDGF stimulation.
Glucocorticoid
Glucocorticoid-induced insulin resistance (DEX) was created with 20 nMdexa-
methasone (0.01% ethanol carrier as control) changed every other day for
8 days. On day 8, the cells were washed three times with PBS and incubated
for 90 min in stepdown medium before acute stimulation.
Palmitate
Palmitate (PALM) was conjugated to 20% BSA in culture medium at 5-fold of
the final concentration. BSA/palmitate or BSA/ethanol (control) was heated to
50C for 20 min, cooled to 37C, and diluted five times with culture medium
before filter sterilizing. The flowthrough was delivered to cells at the specified
doses with a final BSA concentration of 4% in all treatments. The complete
treatment lasted 18 hr and consisted of two additions of palmitate. The first
treatment was performed in the presence of 2% fetal calf serum for 16.5 hr, af-
ter which the myotubes were washed three times with PBS, and the second
incubationwas identical to the first except that it was performedwithout serum
for 90 min prior to acute stimulation with insulin or PDGF.
All insulin-resistance treatment regimens were initiated in 3T3-L1 adipo-
cytes between 7 and 12 days postdifferentiation and in L6 myotubes between
6 and 9 days postdifferentiation. After the insulin-resistance treatment, 100 nM
insulin or 20 ng/ml PDGF was added to the cells for 20 min before harvest or
analysis of GLUT4 translocation. Total GLUT4 protein levels were measured
by western blot following each treatment condition. While we did not observe
a significant change in GLUT4 levels following GO, CI, or PALM treatments,
GLUT4 levels were increased by 22% and 94% after treatment with TNF
and DEX, respectively (data not shown). Therefore, all measures of GLUT4
translocation were normalized to total GLUT4 and are represented as the
percent of GLUT4 at the plasma membrane.
Animals
Male C57BL/6 mice overexpressing PDGFR in muscle were obtained from
Yuasa et al. (2004). Homozygous transgenic mice (clone #2) were fed
a chow diet until 8 weeks of age, when they were split into two groups. One
group was maintained on standard lab chow (8% of calories from fat, 21%
of calories from protein, 71% of calories from carbohydrates; 2.6 kcal/g),
and the other was switched to a high-saturated-fat diet (45% of calories
from fat, of which 87% was lard and 13% safflower oil by weight, 20% of cal-
ories from protein, and 35% of calories from carbohydrates; 4.7 kcal/g; based
on Rodent Diet #D12451 [Research Diets, Inc.]) for a period of 17 days or
6 weeks. Mice were housed in a temperature-controlled room (22C ± 1C)
on a 12 hr light/dark (0700/1900) cycle.
Materials
Rat recombinant PDGF-BB, puromycin, dexamethasone, biotin, isobutylme-
thylxanthine, pyruvate, mannitol, thin-layer chromatography plates, potassium
oxalate, andglucoseoxidasewere fromSigma.Geneticin, 1003penicillin/strep-
tomycin/glutamine solution, NuPAGE precast gels, DMEM, and a-MEM were
from Invitrogen. [1-14C]mannitol, 2-[2-6-3H]deoxyglucose, and [g-32P]ATP
were fromGEHealth Care. Fetal calf serumwas from Thermo (Melbourne, Aus-
tralia). Standard rodent chow was from Gordon’s Specialty Stock Feeds. The
Akt1/2 inhibitor was obtained from Symansis; details on its characterization
can be found elsewhere (DeFeo-Jones et al., 2005).
Antibodies
Phospho-Ser473 Akt, phospho-Thr308 Akt, total Akt, and phospho-GSK3
were from Cell Signaling Technology. Antibodies against IR, PDGFR, IRS1,
and phospho-Tyr99 (used in PI3K assays) were from Santa Cruz Biotechnol-
ogy. Phospho-Tyr IR and phospho-Tyr IRS antibodies were from Millipore430 Cell Metabolism 7, 421–433, May 2008 ª2008 Elsevier Inc.(formerly Upstate Biotechnology). The phospho-Thr642 TBC1D4 antibody
was created for us by Symansis.
Animal Experiments
Intraperitoneal (i.p.) glucose tolerance tests (GTTs) were performed onmice on
the morning of sacrifice. Mice were fasted for 4 hr (0730–1130) before i.p.
injection of 25% glucose solution at a dose of 2g/kg. Blood glucose was
measured by sampling blood from the tail tip with an Accu-Chek II glucometer.
After the GTT, mice were killed by cervical dislocation, soleus muscles were
rapidly dissected tendon to tendon, and in vitro 2-DOG uptake was measured
as described previously (Turner et al., 2007).
Soleus muscles (10 mg) were processed for immunoblotting by homoge-
nizing at 4C with 250 ml of 13 PBS (pH 7.4) containing 1 mM EDTA, 30 mM
sodium pyrophosphate, 10 mM NaF, 150 mM NaCl, 2 mM Na3VO4, 1% NP-
40, 10% glycerol, and 13 protease inhibitor cocktail (Roche) using a Polytron
instrument (Kinematica). The lysates were rotated at 4C for 1 hr before being
centrifuged at 16,0003 g for 15min at 4C. Supernatant protein concentration
was determined by the bicinchoninic acid (BCA) method (Pierce).
All experiments were carried out with the approval of the Garvan Institute/St.
Vincent’s Hospital Animal Experimentation Ethics Committee following
guidelines issued by the National Health and Medical Research Council of
Australia.
Immunoblots
3T3-L1 and L6 cultures were washed twice with cold PBS before harvesting
with HES buffer (pH 7.4) containing 2% SDS. Lysates were sonicated for 15 s
and centrifuged at 15,0003 g for 20 min at 15C. Supernatants were then as-
sayed for protein content by BCA assay. Homogenates from soleus muscle
were prepared as described above. Clarified lysates were then diluted with
43 Laemmli buffer and heated to 65C for 3 min. Equal amounts of protein
were electrophoresed through self-made 8% polyacrylamide gels or NuPAGE
precast gradient gels, transferred to PVDF membranes, and blocked with 5%
BSA in Tris-buffered saline (TBS) for 1 hr. Blockedmembranes were incubated
overnight at 4C in primary antibodies diluted in TBS-0.1% Tween 20 (TBST)
containing 5% BSA and 0.05% sodium azide. The following morning, mem-
branes were incubated for 0–2 hr more at room temperature and washed for
30min in TBST. Membranes were then incubated with their respective fluores-
cently labeled secondary antibodies diluted in TBST + 5%BSA + 0.1% SDS in
the dark at room temperature for 1 hr andwashed three times for >30min in the
dark. Membranes were then developed and quantified using a LI-COR Odys-
sey infrared imaging instrument and software. 14-3-3 expression and Ponceau
staining were utilized as loading controls for these experiments.
PI3K Activity Assays
These assays were performed as described previously (Wang and Summers,
2003).
GLUT4 Translocation Assays
These assays were performed as described previously (Govers et al., 2004).
Statistical Analyses
Data are expressed as means ± SEM. For GLUT4 translocation analysis,
unless otherwise specified, each experiment was normalized to 100% of max-
imal insulin before comparison across experiments to decrease interassay
variation and allow direct comparison across all insults of the same cell
type. p values were calculated by two-tailed Student’s t test using Microsoft
Excel or GraphPad Prism. Statistical significance was set at p < 0.05.
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